Compare BridgeBio Pharma Inc (BBIO) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs MGM Resorts International — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while MGM Resorts International trades at $43.5 (market cap $10.91B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MGM | |
|---|---|---|
Market Cap | $16.61B | $10.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $50.69 |
52-Week Low | $47.29 | $30.72 |
Enterprise Value | $18.16B | $38.21B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
MGM Resorts International (MGM) trades at $44.47, down 0.51% on the day, with a bearish technical signal and neutral oscillators. The company reported record Q2 2026 revenue but missed earnings estimates, with net income margin at 2.4% and ROE at 15.44%. Recent news includes a potential acquisition investigation and BetMGM's expansion in Canada, while cash flow trends show improving net cash flow projections for 2026.
Outlook is mixed: analyst consensus leans neutral with a $51.14 price target, but risks include regulatory scrutiny and competitive pressures. The stock offers value with a P/S of 0.66, but investors should weigh earnings volatility and debt levels against growth in digital and Las Vegas operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
